The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for U01 Research Projects to form the NCI-led PDAC Stromal Reprogramming Consortium (PSRC). The overarching objective of the PSRC is to develop a comprehensive understanding of PDAC tumor progression, its microenvironment (TME) as a tumor fate determinant and the reciprocal tumor-TME interactions that drive clinical outcomes. The information obtained through these comprehensive studies should expose new biology-backed vulnerabilities that will inform the development and preclinical testing of novel interventions in PDAC. Central to the PSRC structural organization is the implementation of multidisciplinary team science approaches that iteratively bridge basic and translational research across the tumor-TME continuum in each U01 Research Project, in trans-PSRC activities, and in collaboration with other NCI-funded mechanisms and programs whenever possible.
Letter of Intent Due Date(s): 30 days prior to the application due date.
Application: Nov. 1, 2021
RFA-CA-21-041 Expiration Date: November 02, 2021
Application budgets for each U01 may not exceed $600K in direct costs per year and need to reflect the actual needs of the proposed project.
Applicants may request up to 5 years of support.